Multiple Sclerosis Drugs - Chad

Chad

The Multiple Sclerosis Drugs market in Chad is anticipated to witness a significant growth in revenue, with projections indicating a staggering figure of US$0.71m in 2024.
This revenue is expected to steadily increase with an annual growth rate (CAGR 2024-2029) of 0.56%, ultimately leading to a market volume of US$0.73m by 2029.
On a global scale, United States is expected to dominate the market in terms of revenue generation, with an impressive amount of US$11,770.00m projected for 2024.
Chad's limited access to healthcare infrastructure hinders the availability and affordability of Multiple Sclerosis drugs in the country.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

Multiple Sclerosis (MS) is a chronic and debilitating autoimmune disease that affects the central nervous system. The disease is characterized by inflammation, demyelination, and axonal damage, which can lead to various physical and cognitive symptoms. The MS Drugs market in Chad is still in its infancy stage, with limited availability of drugs and low awareness about the disease among the population.

Customer preferences: The MS Drugs market in Chad is largely driven by the preferences of healthcare providers and patients. The limited availability of drugs in the market has led to healthcare providers prescribing drugs that are not specifically designed for MS treatment. Moreover, the lack of awareness about the disease among the population has resulted in patients seeking treatment for their symptoms rather than the underlying disease.

Trends in the market: The MS Drugs market in Chad is expected to grow in the coming years, driven by an increase in the prevalence of the disease and the availability of new drugs in the market. The market is expected to witness a shift towards disease-modifying therapies (DMTs), which can slow down the progression of the disease and improve patient outcomes. The introduction of oral DMTs in the market is expected to further boost market growth, as they offer convenience and ease of administration compared to injectable DMTs.

Local special circumstances: Chad is a low-income country with limited healthcare infrastructure and resources. The country faces several challenges in providing adequate healthcare to its population, including a shortage of healthcare workers, inadequate funding, and poor healthcare facilities in rural areas. These challenges have a significant impact on the MS Drugs market in Chad, as they limit the availability and accessibility of drugs for patients.

Underlying macroeconomic factors: The MS Drugs market in Chad is influenced by several macroeconomic factors, including the country's GDP, healthcare expenditure, and regulatory environment. Chad has a low GDP per capita, which limits the affordability of drugs for patients. Moreover, the country has a low healthcare expenditure, which limits the government's ability to invest in healthcare infrastructure and resources. The regulatory environment in Chad is also a major challenge for the MS Drugs market, as the country lacks a comprehensive regulatory framework for drug approval and pricing. This has led to a lack of transparency in drug pricing and limited availability of drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.